Advertisement
Organisation › Details
Minervax ApS
MinervaX is a Danish biotechnology company, established in 2010 to develop a prophylactic vaccine against Group B Streptococcus (GBS), based on research from Lund University. MinervaX is developing a GBS vaccine for maternal immunization, likely to have superior characteristics compared with other GBS vaccine candidates in development. The latter are based on traditional capsular polysaccharide (CPS) conjugate technology. By contrast, MinervaX’s vaccine is a protein-only vaccine based on fusions of highly immunogenic and protective protein domains from selected surface proteins of GBS (the Alpha-like protein family). Given the broad distribution of proteins contained in the vaccine on GBS strains globally, it is expected that MinervaX’s vaccine will confer protection against virtually 100% of all GBS isolates. *
Start | 2010-01-01 established | |
Predecessor | University of Lund (Lund University) | |
Industry | vaccine | |
Region | København (Copenhagen) | |
Country | Denmark | |
Street | 3 Ole Maaløes Vej | |
City | 2200 København N | |
Address record changed: 2022-12-17 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Minervax ApS. (12/15/22). "Press Release: Minervax Announces 72M EUR Financing to Advance Development of Novel Vaccine against Group B Streptococcus". Copenhagen. | ||
Record changed: 2024-02-12 |
Advertisement
More documents for Minervax ApS
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top